Starling Oncology, Inc. (STLN)
NASDAQ: STLN · Real-Time Price · USD
5.17
+0.04 (0.78%)
At close: Aug 4, 2026

Starling Oncology Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
51735023150123714
Market Cap Growth
53.67%1400.09%-84.48%22.52%-82.81%-
Enterprise Value
59842699181139808
Last Close Price
5.243.560.312.041.659.75

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----1805.81-
PS Ratio
0.960.700.060.460.493.52
PB Ratio
--22.286.512.641.006.86
P/TBV Ratio
---4.721.4712.05

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
1.100.850.250.560.553.98

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-6.44-6.6034.312.100.880.00
Net Debt / Equity Ratio
-4.58-4.4620.480.650.28-1.10
Net Debt / EBITDA Ratio
-2.88-2.41-1.36-0.68-0.512.71
Net Debt / FCF Ratio
-2.90-2.53-2.42-0.90-0.513.21
Asset Turnover
3.292.982.061.381.091.51
Inventory Turnover
25.3231.6828.6223.0825.5330.05
Quick Ratio
1.131.311.883.623.844.55
Current Ratio
1.471.592.154.134.395.17
Return on Equity (ROE)
---213.36%-92.20%0.13%-16.52%
Return on Assets (ROA)
-12.30%-13.37%-19.67%-15.97%-19.35%-21.08%
Return on Invested Capital (ROIC)
-35.80%-42.26%-70.35%-47.85%-97.58%-377.00%
Return on Capital Employed (ROCE)
-36.80%-38.50%-49.90%-34.50%-31.00%-26.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-6.94%-17.30%-276.96%-55.21%0.12%-1.53%
FCF Yield
-4.92%-7.93%-129.89%-27.17%-54.80%-4.98%
Buyback Yield / Dilution
-30.10%-23.11%-1.76%8.51%-21.70%-12.03%